Quest Diagnostics (DGX) Tops Q2 EPS by 210c

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $4.96, $2.10 better than the analyst estimate of $2.86. Revenue for the quarter came in at $2.55 billion versus the consensus estimate of $2.38 billion.

GUIDANCE:

Quest Diagnostics sees FY2021 EPS of $10.65-$11.35, versus the consensus of $11.13. Quest Diagnostics sees FY2021 revenue of $9.54-9.79 billion, versus the consensus of $9.45 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• General Aerospace (GE) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY26 EPS Guidance
• VIST Financial Corp. (VIST) Misses Q2 EPS by 76c